Annexon to present on the neuroprotective effects of anx007 at the 2025 arvo annual meeting and the retina world congress

Phase 2 archer data support therapeutic potential for anx007 to preserve vision in patients who have dry age-related macular degeneration (amd) with geographic atrophy (ga) phase 3 archer ii trial enrolling globally brisbane, calif., may 07, 2025 (globe newswire) -- annexon, inc. (nasdaq: annx), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced presentations on the neuroprotective effect of anx007, including consistent benefits of c1q inhibition against inflammation and neuronal damage across diseases.
ANNX Ratings Summary
ANNX Quant Ranking